Kornimate/medical-research-clean huggingface dataset:
accuracy and feasibility of xpert ultra

Conditions: Tuberculosis, Pulmonary

Summary: consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. in the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.


Eligibility criteria:
case detection group inclusion criteria: * age 18 years or above; * provision of informed consent; * willingness to provide 4 sputum specimens at enrolment; * willingness to have a study follow-up visit approximately 42 to 70 days after enrolment * clinical suspicion of pulmonary tb (including cough ≥2 weeks and at least 1 other symptom typical of tb) exclusion criteria: * receipt of any dose of tb treatment within 6 months prior to enrolment * participants for whom, at the time of enrolment, the follow-up visit is judged to be poorly feasible (e.g. individuals planning to relocate) drug-resistant tb group inclusion criteria: * age 18 years or above; * provision of informed consent; * willingness to provide 4 sputum specimens at enrolment; * non-converting pulmonary tb cases (category i and category ii failures) or multi-drug resistant (mdr) suspect\* (based on world health organization definition), i.e. at least one of the following: i) retreatment cases, ii) active tb cases that are mdr-contacts and iii) patients at high risk for mdr-tb as determined by local program (e.g. prisoners) exclusion criteria: • none

Keywords: diagnosis xpert mtb/rif ultra xpert mtb/rif
temporamandibular joint functions and parafunctional habits

Conditions: Headache; Temporomandibular Disorder

Summary: headache is the most common type of pain in children and adolescents with effects on health-related quality of life (hrqol), school attendance, and social functioning. the international headache society recognizes that secondary headaches can be attributed to temporamandibular joint (tmj) problems. the primary aim of the study is to evaluate temporamandibular joint functions and parafunctional habits in adolescents with headache. the second aim is to examine the relationship between temporamandibular joint functions and parafunctional habits and headache.

24 individuals under the age of 18 diagnosed with headache and 24 healthy controls will be included in the study. age, height, weight characteristics and parafunctional habits of individuals will be recorded. the severity of headache and its effect on daily life, temporamandibular joint pain severity will be evaluated. temporamandibular joint dysfunction severity will be determined and mouth openings will be measured. participants who meet the inclusion criteria will be included in the study group. healthy volunteers without headache complaints will also be included in the study as a control group.in this study, which is planned to include those who meet the inclusion criteria and agree to participate in the study, written informed consent form will be obtained from all individuals and from their parents for those under the age of 18. the study will be carried out in accordance with the ethical principles of the declaration of helsinki. the study will be done through a questionnaire form and with anthropetric measurements. no invasive procedure will be applied. a p value of ≤0.05 will be considered significant in all statistics.

Eligibility criteria:
inclusion criteria: * being diagnosed with headache according to the icdh-ii (international classification of headache disorders 2nd edition) criteria published by ihs (international headache society) in 2004 * having a headache complaint in the last 3 months * having a hit-6 score of 50 or higher exclusion criteria: * being on any analgesic, anti-sedative, myorelaxant medication * those with mental and psychiatric problems

Keywords: adolescent headache temporomandibular dysfunction
comparison study of eap and cg regimens for mobilizing hematopoietic stem cells in multiple myeloma patients

Conditions: Multiple Myeloma; Hematopoietic Stem Cell Mobilization

Summary: this is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and pegfilgrastim (eap regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (ndmm). a total of 99 ndmm patients will be enrolled and randomly assigned to receive either the eap regimen or the gc regimen (cyclophosphamide+ g-csf) to mobilize hematopoietic stem cells. subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.

according to strict inclusion and exclusion criteria, 99 newly diagnosed mm patients will be selected. they will be randomly assigned in a 2:1 ratio to the eap group or the cg group. during the hematopoietic stem cell mobilization period, comparison study will be conducted regarding the proportion of patients who achieve the ideal collection value (cd34 cells \>5×10\^6/kg) after a single collection; the proportion of patients who cumulatively achieve the target collection value (cd34 cells \>2×10\^6/kg) and the ideal collection value; the cumulative collection of cd34 cells and the average number of collections; and the hematological and non-hematological adverse reactions of the eap and cg regimens. special attention will be given to the proportion of patients who add plerixafor in both regimens.

Eligibility criteria:
inclusion criteria: * 1. patients newly diagnosed as multiple myeloma. * 2. indication for asct. * 3. eastern cooperative oncology group (ecog) performance status of 0\~1. * 4. life expectancy ≥ 3 months. * 5. subjects must be able to understand the protocol and sign the informed consent. exclusion criteria: * 1. cardiac function class ii or higher or cardiac ejection fraction \<40%. * 2. serum direct bilirubin (dbil)\>2× upper limit of normal (uln). * 3. aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>3× uln. * 4. serum creatinine clearance rate≤30%. * 5. patients with active infection. * 6. previously received hematopoietic stem cell mobilization.

Keywords: multiple myeloma etoposide cytarabine peg-rhg-csf hematopoietic stem cell mobilization
clinical effect of chlorhexidine mouthwash after periodontal surgery

Conditions: Periodontal Diseases; Periodontitis; Dental Plaque

Summary: chlorhexidine is the gold standard of dental plaque prevention. recent research have demonstrated that 0.2% chlorhexidine solutions are more effective than 0.12% and 0.06% chlorhexidine solutions. several 0.2% solutions are available on the market. this study aimed to compare effectiveness of two commercially available 0.2% chlorhexidine mouthwashes. patients, that after initial periodontal therapy, had a need for two periodontal surgeries, will be invited to join. after one surgical session, the patient will receive one 0.2% chlorhexidine solution, and after the next surgical session the patient will receive the other 0.2% chlorhexidine solution. plaque and gingivitis will be recorded, as well as side effects.


Eligibility criteria:
inclusion criteria: periodontitis, stage iii and iv exclusion criteria: uncontrolled diabetes systemic conditions associated with excessive bleeding uncontrolled hypertension

Keywords: periodontal index
post operative hemodynamic function after anesthetic induction with etomidate for cardiac surgery with ecc

Conditions: Cardiac Surgery

Summary: because of its hemodynamic safety, etomidate is widely used for anaesthesia induction of cardiac surgery. it can also cause adrenal insufficiency during the following 48 hours ( 11 betahydroxylase inhibition ). so it could increase hemodynamic dysfunction caused by the sirs following cardiopulmonary bypass. a previous observational study found more adrenal insufficiency and need for vasopressive support therapy in the etomidate group versus another propofol induced group. the aim of our work is to compare hemodynamic dysfunction following induction with etomidate for cardiac surgery with ecc. the control group would be induced by propofol. 94 patients would be included.

information will be given at the anaesthetic consultation, few weeks before planed cardiac surgery. eligibility and exclusion criteria will be checked. patient will receive an informative written consent notice and all questions will be answered. a standard pre-operative blood collection will be sampled. in order to minimize the potential confusing effect of daily cortisol variation, only surgical procedure performed early morning will be considered. the day before surgery definitive inclusion will be decided as the order of procedure is not known before. only patients operated in the morning will be included because of cortisol daily variations. at this time, consent and information notice will be signed and checked in the medical record. on the morning of surgery, during venous catheter insertion an additional blood sample will be collected to asses basal cortisolemia. randomisation will be carried out centrally after patient operative theatre admission, by phone call from icu to randomisation office. hypnotic drug will be prepared in the icu department next to the operative room and blindly administered to patient ( same volume per weight ). all other anesthetic procedures will be standardised : opioid drugs, vasopressive support, antifibrinolytics and hemodynamic monitoring. after surgery patients are admitted to surgical icu. they will undergo standard post operative exams plus two corticotrophin tests and a dosage of sirs markers ( il6 and tnf alpha ). these results will only be known at the end of the study.

Eligibility criteria:
inclusion criteria: * age superior to 18 years * patient which had to be operated for aorto-coronary pass and/or valvular replacement exclusion criteria: * patient with aortics shrinking * women pregnant or nursing * contra-indication to etomidate or diprivan or synacthene * patient with insufficiency kidney * patient with infection

Keywords: cardiac surgery adrenal insufficiency etomidate propofol
effects of transfusion of older stored red cells

Conditions: Sickle Cell Disease; Thalassemia

Summary: the purpose of this study is to determine the effects of transfusion of fresh and stored blood on patients. the investigators hope to test: * whether a similar effect (older stored blood is associated with worse outcomes) is seen in chronically transfused patients with hemoglobinopathies. this patient population will also allow the investigators to test whether iron- chelation therapy is beneficial in this setting. * whether washing or cryopreserving the red blood cells has any effect on this outcome. these findings may explain the immunomodulatory effects of older stored blood in patients and will help us develop safer transfusion products for patients.

epidemiologic studies suggest that older stored blood is associated with worse outcomes in certain hospitalized patients. storage of red cells is associated with a storage lesion and the survival of transfused red cells decreases with increasing storage time, thus older blood is associated with an increased acute delivery of hemoglobin-iron to the reticuloendothelial system. the investigators have preliminary data in healthy human volunteers suggesting that delivery of a significant iron load to the reticuloendothelial system from aged red cells leads to the elaboration of a potentially toxic form of iron known as non-transferrin-bound iron.

Eligibility criteria:
inclusion criteria (recipient): * specific, well-characterized hemoglobinopathy * chronic simple transfusion therapy (transfusion episodes \< 6 weeks apart in frequency) * chronic iron chelation therapy * not pregnant by self-report and not planning pregnancy * age \> 1 year old exclusion criteria (recipient): * clinically unstable * treatment for mental illness * imprisonment * institutionalization inclusion criteria (donor): * 21-65 years of age * male weight \> 130 lbs, female weight \> 150 lbs * male height \> 5'1", female height \> 5'5" * hemoglobin \> 15.0 g/dl * reasonably certain of intention to stay in new york city metropolitan area for study duration * previously tolerated red blood cell donation exclusion criteria (donor): * ineligible for donation based on new york blood center blood donor screening questionnaire * systolic blood pressure \ 180 mm hg, diastolic blood pressure \ 100 mm hg * heart rate \ 100 * temperature \> 99.5 f prior to donation * positive by standard infectious disease testing performed on blood donors

Keywords: iron transfusion red blood cells sickle cell disease thalassemia blood donors
oxaliplatin-induced portal hypertension

Conditions: Gastroesophageal Varices Hemorrhage; Colorectal Cancer; Received Oxaliplatin-based Chemotherapy

Summary: oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. however, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. the pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. in this current study, we aim to evaluate the efficacy of individualized treatment in patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.


Eligibility criteria:
inclusion criteria: * sign written informed consent * male or female patients aged 18-75 * diagnosed as portal hypertension by contrast-enhanced computed tomography * and confirmed gastroesophageal varices by upper digestive endoscopy; * had a history of oxaliplatin-based chemotherapy after colorectal cancer surgery; exclusion criteria: * combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease. * with colorectal cancer required further anti-tumor treatment * other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.

Keywords: portal hypertension gastroesophageal variceal bleeding colorectal carcinoma splenomegaly oxaliplatin
trial to examine the effect of natural anti- obesity agent (phaseolus vulgaris) among women of lahore

Conditions: Overweight and Obesity

Summary: this double-blind randomized placebo-controlled trial will test the hypothesis that administration of phaseolus vulgaris supplementation to women in lahore, pakistan, who are overweight will induce the weight loss (primary outcome) and changes in body composition (waist circumference) secondary outcome.


Eligibility criteria:
inclusion criteria: * bmi ranges from 25-40 * consistently stable body weight for at least 6 months * good general health * no ongoing drug treatment for weight reduction * commitment to avoid any changes in lifestyle throughout the test period * age between 18-45 years * women resident of lahore exclusion criteria: * pregnant or breast-feeding females * people with type 2 diabetes * people with any other chronic diseases * weight reduction treatment during the 6 months prior to the study

Keywords: weight loss
the cork and kerry diabetes and heart disease study (phase ii) mitchelstown cohort

Conditions: Cardiovascular Diseases; Diabetes; Obesity; Hypertension; Dyslipidemia; Metabolic Syndrome; Diet Habit; Life Style; Physical Activity; Smoking

Summary: the aim of the cork and kerry study phase ii (mitchelstown cohort recruited 2010-11) is to provide an updated profile of glucose tolerance status, cardiovascular health and their related factors in an irish adult general population sample and to compare the findings with those obtained during baseline assessment of phase i of the cork and kerry study (1998) and the rescreen (2008).

additional objectives include determining the prevalence of proximal risk factors, such as hypertension, dyslipidaemia, body mass index (bmi) and insulin resistance as well as of more distal risk factors of diet, smoking, alcohol consumption and physical activity, and the association between cardiovascular health and its risk factors with general measures of well-being and mental health. the new cohort includes collection of qualitative and quantitative data in an effort not only to describe the current health status of the cohort and assess individual level determinants but also to provide the appropriate context to interpret the role of behavioural factors and social circumstances on health. recruitment was completed on a new cohort of 2047 men and women aged 50-69 years from patients attending a single large primary care centre, the living health clinic in mitchelstown, a town with a population of 43000 in county cork. the living health clinic includes eight gps, and the practice serves a catchment area of 20 000, with a mix of urban and rural residents. participants were randomly selected from all registered attending patients in the 50-69-year age group.

Eligibility criteria:
inclusion criteria: all participants from the livinghealth clinic practice list in the 50-69 year age bracket exclusion criteria: duplicates, deaths and ineligibles and those who did not complete the general health questionnaire and physical examination
a community-based intervention among active drug users in montpellier

Conditions: Drug Use; HCV Infection

Summary: the study aims to assess the effectiveness of a community-based model of hcv mass screening associated with an immediate hcv treatment on the cascade of care among active drug users (dus) in the city of montpellier, france.

active dus will be recruited using a respondent-driven sampling (rds) method. hosted in the temporary community care facility (the research site), located outside the existing care facilities in the city, participants will benefit from hcv/hiv/hbv screening, on-site measurement of hcv-rna and liver fibrosis, early treatment, treatment follow-up and risk and harm reduction tools related to their risk practices. peers will be present in this unique structure and will accompany participants throughout their treatment. participants will be referred during treatment to existing care facilities but followed up in the research up to 44 to 48 weeks after initiation of treatment to assess the rate of re-infection. the number of active dus in the population will be estimated by using a capture/recapture method nested in the rds survey secondary objectives of the research are: * to estimate the seroprevalence of hepatitis c in active dus in montpellier; * to estimate the size of the active dus population in the city of montpellier using a capture/recapture method; * to estimate hcv care cascade steps in active dus in montpellier; * to identify the factors associated with hcv treatment failure; * to determine the proportion of treated and cured hcv patients who re-infect within months after end of treatment; * to estimate the seroprevalence of hepatitis b and hiv infection in active dus in montpellier.

Eligibility criteria:
inclusion criteria: * age\> 18 years * be an active drug user defined by: 1. report current and regular (last uptake no more than 3 days ago and at least 10 times a month) use of illicit psychoactive substances other than cannabis (heroin, amphetamines, cocaine, mdma/ecstasy, cathinones) or misused medications (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine) and 2. positive urine test for a psychoactive substance other than cannabis (heroin, amphetamines, cocaine, mdma/ecstasy, cathinones) or a misused medication (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine). exclusion criteria: * inability to understand the study * be under guardianship, curatorship or future protection mandate * lack of informed consent

Keywords: hepatitis c rds survey communauty-based intervention viral hepatitis c
high-volume vs low-volume preparation in emergency department

Conditions: GastroIntestinal Bleeding

Summary: the primary endpoint of this study was to compare the intestinal cleansing of patients with lgib requiring colonoscopy, prepared with high-volume or with low-volume who have to perform colonoscopy, directly from the ed. the intestinal cleansing was evaluated with the standardized boston bowel preparation scale (bbps). the secondary endpoint was to evaluate the tolerability and compliance of patients prepared with high-volume in comparison to low-volume in the ed.


Eligibility criteria:
inclusion criteria: * males or females * \> 18 years and \<85 years, * hemodynamically stable, * able to sign informed consent * requiring colonoscopy * anemia (loss of at least 2 g/dl of hb) with or without active bleeding exclusion criteria: * suspected or confirmed pregnancy, * hemodynamically unstable patients, * patients unable to swallow or with known or suspected gastrointestinal obstruction or perforation, * toxic megacolon, * major colonic resection, * heart failure (class iii or iv nyha), * severe liver failure, * end-stage renal disease
loteprednol and tobramycin versus tobramycin and dexamethasone, in the treatment of blepharokeratoconjunctivitis

Conditions: Conjunctivitis; Keratitis; Blepharitis

Summary: this study is to evaluate the safety and efficacy of loteprednol etabonate \[le\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (bkc).


Eligibility criteria:
inclusion criteria: * subjects must have a clinical diagnosis of bkc in at least one eye * subjects must be willing to discontinue contact lens use for the duration of the study * subjects who are able and willing to comply with all treatment and follow- up/study procedures. exclusion criteria: * subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation. * subjects who have any uncontrolled systemic disease or debilitating disease. * subjects who have a known hypersensitivity to the study drugs or their components (including benzalkonium chloride) or contraindications to tobramycin or ocular corticosteroids. * subjects who use any topical or systemic ophthalmic medications listed as disallowed in the study protocol, within the specified time frame prior to visit 1. * subjects who have a disease or conditions which the investigator determines could interfere with the safety and efficacy evaluations of the study drug. * subjects having ocular surgery (including laser surgery) in either eye within the past three months.

Keywords: blepharokeratoconjunctivitis
staccato prochlorperazine single dose pk study

Conditions: Migraine

Summary: the objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine

the objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of a single, inhaled dose of prochlorperazine (pcz), administered as 1 or 2 puffs in healthy young volunteers.

Eligibility criteria:
inclusion criteria: * subjects will be male or female subjects between the ages 18 to 45 years, inclusive in good general health as determined by medical history, physical examination, 12-lead ecg, spirometry, blood chemistry profile, hematology, urinalysis and in the opinion of the principal investigator. exclusion criteria: * subjects with a known history of allergy or intolerance to phenothiazines or related drugs or who have any disease, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.

Keywords: migraine, prochlorperazine aerosol